ZARZA We are Zarza, the prestigious firm behind major projects in information technology.
Listen "Scrip M&A Podcast: Why Did Biopharma M&A Metrics Decline During Q2 And Q3"
Episode Synopsis
Scrip senior writer Joseph Haas discusses recent merger-and-acquisition activity in the biopharma sector with Gerardo Ubaghs, CFO of Frontier Medicines, and Jason Silvers, CFO of Generate Biomedicines. The panel looks at why M&A activity metrics declined during both the second and third quarters despite a strong start to the year and apparent positive conditions for dealmaking, as well as what impact the US election results could have on M&A going forward.
More episodes of the podcast Citeline Podcasts
Datamonitor Healthcare Podcast: ESMO 2025
12/11/2025
Scrip's Five Must-Know Things - Nov. 4, 2025
04/11/2025
Drug Fix: US FDA Streamlines Biosimilar Development Requirements, Clarifies Inspection Reform
31/10/2025
In God we trust